Dormant tumor cells as a therapeutic target?

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Tumor dormancy involves residual cancer cells persisting long-term, a major cause of cancer recurrence and death.
• Minimal residual disease (MRD) recurrence highlights the need to understand dormancy mechanisms for relapse prevention.

Purpose of the Study:

• To explore the mechanisms by which cancer cells enter and maintain a dormant state.
• To identify strategies for preventing cancer relapse by targeting dormant tumor cells.

Main Methods:

• Review of evidence on the host-dormant tumor cell balance.
• Analysis of tumor cell-micro-environment cross-talk, angiogenesis, and anti-tumor immunity.
• Examination of cancer cell immune escape mechanisms.

Main Results:

• A balance exists between the host and dormant tumor cells, influencing recurrence.
• Tumor cells employ mechanisms like immuno-regulatory molecule expression (B7.1, B7-H1), epigenetic modifications (SOCS1 gene silencing, JAK/STAT pathway deregulation), and autocrine loops for immune escape and equilibrium.
• Interactions with the micro-environment, angiogenesis, and immune responses are critical in controlling dormant cells.

Conclusions:

• Understanding tumor dormancy mechanisms provides new therapeutic opportunities.
• Targeting these mechanisms can shift the balance towards the host immune response, potentially preventing cancer relapse.